Antithrombotic Drugs: World Market 2013-2023

February 2013 | 119 pages | ID: A131109ED3FEN
Visiongain

Abstracts

Antithrombotic agents - discover technological and commercial prospects

What does the future hold for treating conditions associated with thrombosis? Visiongain's updated report gives you forecasted revenues to 2023, explaining R&D trends, outlooks and opportunities.

Our study lets you assess sales data for the world market, submarkets, products and national markets. There you find that industry's most promising and lucrative segments.

Therapies modifying blood clotting have rising demand. Also, emerging technologies hold promise. See the future of medicines for reducing thrombus formation.

Forecasts and other analyses to help you stay ahead in knowledge

In our report you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends (R&D). You gain 70 tables, 41 charts and four research interviews.

Is finding commercial details a challenge? With our report you can get ahead in knowledge, benefiting your research, analyses and decisions. Find trends, innovations and opportunities. You see what's happening.

There's rising demand for those drugs. Discover areas that will prosper, reducing the risk of your being left behind.

The following sections show how you benefit from our new study.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market for that field, you see forecasts to 2023 for these submarkets:

• Platelet aggregation inhibitors
• Anticoagulants
• Fibrinolytics.

The study also forecasts anticoagulant subclasses:

• Heparins
• Vitamin K antagonists
• Direct thrombin inhibitors
• Direct factor Xa inhibitors
• Other agents.

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing treatments likely to achieve the most success.

See revenue forecasts for products

How will leading antithrombotics perform to 2023 at world level? Our work shows you revenue forecasts for 14 top products, including Plavix, Lovenox, Pradaxa, Pletal and Aggrenox, as well as newer drugs, Effient, Brilinta, Xarelto and Eliquis.

Discover how high revenues can go, to 2023, finding areas and years with highest predicted growth. You see what's happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What prospects for leading countries?

Developments worldwide will influence the market, especially rising demand in emerging countries - e.g. Brazil and China. Our report shows outlooks for the industry.

You see individual forecasts to 2023 for eleven national markets, getting overall revenues:

• US
• Japan
• Germany, France, UK, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC nations).

Discover progress and outlooks. You assess the industry's future - hear about developments and find their significance.

You find potential. Our analyses show growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2013 to 2023 will change medical prescribing and the commercial landscape.

Research and development - assess innovation, trends and possibilities

What about R&D - the pipeline for new drugs? You see trends for these agents:

• Platelet aggregation inhibitors
• Anticoagulants
• Heparins
• Thrombin inhibitors.

Our study also discusses these candidates and others:

• Direct factor Xa agents
• Vitamin K antagonists
• Fibrinolytics
• Small molecules in pre-clinical research.

There's strong, promising R&D for treating thrombosis and related disorders. Novel compounds and new formulations with high safety, efficacy and affordability are in great demand to replace older drugs, especially warfarin. See what's happening.

You assess the future of those cardiovascular treatments, hearing about progress and finding its significance. Our work explains, discussing many issues.

What affects treatment of thrombosis and related disorders?

Our report discusses issues and events affecting that industry and market from 2013, looking ahead:

• Complications of thrombosis - pulmonary embolism, stroke, acute coronary syndrome and myocardial infarction
• Strengths and weaknesses of the antithrombotic drug industry and market
• Oral anticoagulants and therapeutic needs
• Advances in technology that promise medical and commercial benefits
• Rise in disease prevalence.

We also discuss these aspects of the field:

• Need for cost-effective new treatments
• Improvement of existing drugs
• Demand for antidotes - a promising area for development
• Competition - branded products and generics
• Budgetary pressures in healthcare.

You explore technological, economic, social and political questions, assessing companies, competition and outlooks for business. See what the future holds.

Leading companies and 2015 market value

We predict the overall world market for antithrombotic drugs will reach $24.3bn in 2015, and expand further to 2023.

Our study shows you what technologies, products and organisations hold greatest potential. We explore these leading companies:

• Bristol-Myers Squibb
• Sanofi
• Boehringer Ingelheim
• Bayer
• Roche
• GlaxoSmithKline (GSK).

We cover other developers and producers too, including these:

• Otsuka Pharmaceutical Company
• Eli Lilly
• AstraZeneca
• Johnson & Johnson
• Pfizer.

Prospects for R&D are strong, and from 2013 onwards there will arise many opportunities. Our work shows you the technological and commercial possibilities, helping you stay ahead.

Nine ways Antithrombotic Drugs: World Market 2013-2023 helps

To sum up, our investigation gives you the following knowledge:

• Revenues to 2023 for the overall world market and 8 submarkets - you discover that industry's prospects
• Revenues to 2023 for 14 leading products - you find sales outlooks for top brands
• Forecasting to 2023 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - you see leading national sales potentials
• Assessments of companies - you find activities, products, capabilities and outlooks
• Review of R&D by technology - you hear about progress in those research areas, finding technological and medical possibilities
• Interviews with authorities in academia, medicine and industry - you discover debates and opinions to help you stay ahead
• Understanding of competition and opportunities - you see what affects that industry, learning what shapes its future
• Analysis of what stimulates and restrains the industry and market - you assess challenges and strengths, helping you compete and gain advantages
• Prospects for established firms and those seeking to enter the sector - you explore needs, practices and outlooks for success.

You gain information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, also saving time and getting you recognition for insight.

Discover technological and commercial prospects from 2013 by ordering now

Visiongain's investigation is for everyone needing analysis of the industry and market for preventing and treating cardiovascular disorders. You find data, trends and predictions. Please order our report now.

Contents

1. EXECUTIVE SUMMARY

1.1 Antithrombotic Drugs: World Market Overview
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods

2. BLOOD CLOTTING: MECHANISM, DISORDERS AND TREATMENTS

2.1 Thrombosis
  2.1.1 Venous Thrombosis
  2.1.2 Arterial Thrombosis
2.2 Complications of Thrombosis
  2.2.1 Pulmonary Embolism
  2.2.2 Stroke
  2.2.3 Acute Coronary Syndrome
    2.2.3.1 Acute Myocardial Infarction
2.3 Antithrombotic Treatments
  2.3.1 Platelet Aggregation Inhibitors
    2.3.1.1 Glycoprotein Inhibitors
    2.3.1.2 COX Inhibitors (Aspirin)
    2.3.1.3 ADP Antagonists (Including Thienopyridines)
    2.3.1.4 Phosphodiesterase Inhibitors
  2.3.2 Anticoagulants
    2.3.2.1 Heparins
    2.3.2.2 Vitamin K Antagonists
    2.3.2.3 Direct Thrombin Inhibitors
    2.3.2.4 Direct Factor Xa Inhibitors
  2.3.3 Fibrinolytics
    2.3.3.1 Tissue Plasminogen Activator (tPA)
    2.3.3.2 Streptokinase
    2.3.3.3 Urokinase

3. ANTITHROMBOTIC DRUGS: WORLD MARKET 2013-2023

3.1 The Antithrombotic Drug Market in 2011
3.2 The Antithrombotic Drug Market: Revenue Forecast 2012-2023
3.3 Platelet Aggregation Inhibitors
  3.3.1 The Platelet Aggregation Inhibitors Market in 2011
  3.3.2 Platelet Aggregation Inhibitors: Market Forecast 2012-2023
3.4 Anticoagulants
  3.4.1 The Anticoagulants Market in 2011
  3.4.2 Anticoagulants: Market Forecast 2012-2023
  3.4.3 Heparins
    3.4.3.1 The Heparins Market in 2011
    3.4.3.2 Heparins: Market Sector Forecast, 2012-2023
  3.4.4 Vitamin K Antagonists
    3.4.4.1 The Vitamin K Antagonists Market in 2011
    3.4.4.2 Vitamin K Antagonists: Market Sector Forecast, 2012-2023
  3.4.5 Direct Thrombin Inhibitors
    3.4.5.1 The Direct Thrombin Inhibitors Market in 2011
    3.4.5.2 Direct Thrombin Inhibitors: Market Sector Forecast, 2012-2023
  3.4.6 Direct Factor Xa Inhibitors
    3.4.6.1 The Direct Factor Xa Inhibitors Market in 2011
    3.4.6.2 Direct Factor Xa Inhibitors: Market Sector Forecast, 2012-2023
3.5 Fibrinolytics
  3.5.1 The Fibrinolytics Market in 2011
  3.5.2 Fibrinolytics: Market Forecast 2012-2023
3.6 Chapter Summary

4. LEADING NATIONAL MARKETS FOR ANTITHROMBOTIC DRUGS, 2013-2023

4.1 Leading National Markets in 2011
4.2 Leading National Markets: Forecasts to 2023
4.3 The US Antithrombotic Drug Market, 2011-2023
4.4 The Japanese Antithrombotic Drug Market, 2011-2023
4.5 The Leading European Antithrombotic Drug Markets, 2011-2023
4.6 The Chinese Antithrombotic Drug Market, 2011-2023
4.7 The Brazilian Antithrombotic Drug Market, 2011-2023
4.8 The Indian Antithrombotic Drug Market 2011-2023
4.9 The Russian Antithrombotic Drug Market 2011-2023

5. LEADING ANTITHROMBOTIC DRUGS, 2013-2023

5.1 The Leading Drugs of 2011
5.2 Plavix
  5.2.1 Plavix: The Leading Antithrombotic of 2011
  5.2.2 Plavix Revenue Forecast, 2012-2023
  5.2.3 Branded Competition
5.3 Lovenox
  5.3.1 Lovenox Sales, 2011
  5.3.2 Lovenox Revenue Forecast, 2012-2023
5.4 Enoxaparin Sodium: Competition for Lovenox
  5.4.1 Enoxaparin Sodium Sales, 2011
  5.4.2 Enoxaparin Sodium Revenue Forecast, 2012-2023
5.5 Pradaxa
  5.5.1 Pradaxa Sales, 2011
  5.5.2 Pradaxa Revenue Forecast, 2012-2023
  5.5.3 Competition for Pradaxa
5.6 Pletal
  5.6.1 Pletal Sales, 2011
  5.6.2 Pletal Revenue Forecast, 2012-2023
5.7 Aspirin Cardio
  5.7.1 Aspirin Cardio Sales, 2011
  5.7.2 Aspirin Cardio Revenue Forecast, 2012-2023
5.8 Aggrenox
  5.8.1 Aggrenox Sales, 2011
  5.8.2 Aggrenox Revenue Forecast, 2012-2023
5.9 Activase
  5.9.1 Activase Sales, 2011
  5.9.2 Activase Revenue Forecast, 2012-2023
5.10 Angiomax
  5.10.1 Angiomax Sales, 2011
  5.10.2 Angiomax Revenue Forecast, 2012-2023
5.11 Arixtra
  5.11.1 Arixtra Sales, 2011
  5.11.2 Arixtra Revenue Forecast, 2012-2023
5.12 Newly Launched Drugs, 2009-2012
  5.12.1 Eli Lilly's Effient
    5.12.1.1 Effient Revenue Forecast, 2012-2023
  5.12.2 AstraZeneca's Brilinta
    5.12.2.1 Brilinta Revenue Forecast, 2012-2023
    5.12.2.2 Competition for Brilinta
  5.12.3 Johnson & Johnson and Bayer's Xarelto
    5.12.3.1 Xarelto Revenue Forecast, 2012-2023
    5.12.3.2 Competition for Xarelto
  5.12.4 Bristol-Myers Squibb and Pfizer's Eliquis
    5.12.4.1 Eliquis Revenue Forecast, 2012-2023
5.13 Chapter Summary

6. ANTITHROMBOTIC DRUG R&D PIPELINE

6.1 Platelet Aggregation Inhibitors R&D Pipeline, 2012
  6.1.1 Pozen's Aspirin + Omeprazole
  6.1.2 The Medicine Company's Cangrelor
  6.1.3 Merck's Vorapaxar
6.2 The Anticoagulant Drug R&D Pipeline, 2012
  6.2.1 The Heparins Pipeline, 2012
    6.2.1.1 Momenta Pharmaceutical's Adomiparin
    6.2.1.2 Pre-Clinical Research: Sulphated Low Molecular Weight Lignins
    6.2.1.3 The Discontinuation of Semuloparin
  6.2.2 The Vitamin K Antagonist Pipeline, 2012
    6.2.2.1 Armetheon's Tecafarin
  6.2.3 The Direct Thrombin Inhibitors Pipeline, 2012
    6.2.3.1 AstraZeneca's AZD0837
  6.2.4 The Direct Factor Xa Inhibitors Pipeline, 2012
    6.2.4.1 Daiichi Sankyo's Edoxaban
    6.2.4.2 Sanofi's Preluent
    6.2.4.3 Portola Pharmaceutical's Betrixaban
6.3 The Fibrinolytics R&D Pipeline, 2012
  6.3.1 Lundbeck's Desmoteplase
  6.3.2 Bharat Biotech's THR-100
6.4 Other Antithrombotic Drugs: R&D Pipeline, 2012
  6.4.1 Asahi Kasei Pharma America's Recomodulin
  6.4.2 Endotis' EP217609
  6.4.3 ISIS Pharmaceutical's ISIS-Fx Rx

7. THE ANTITHROMBOTIC DRUG MARKET: INDUSTRY TRENDS AND OUTLOOKS

7.1 The Main Drivers and Restraints Affecting the Antithrombotic Drug Market
7.2 The Strengths and Weaknesses of the Antithrombotic Drug Market, 2012
  7.2.1 Thrombotic Diseases: Management Rather Than Cure
  7.2.2 Novel Oral Anticoagulants and the Unmet Market Need
  7.2.3 Advances in Technology Will Bring Benefits to the Market
7.3 The Opportunities and Threats in the Antithrombotic Drug Market, 2013-2023
  7.3.1 Rising Disease Prevalence
  7.3.2 A Cost-Effective Replacement for Warfarin
  7.3.3 Further Development of Existing Drugs
  7.3.4 Antidotes in Demand
  7.3.5 Competition: Branded and Generic
  7.3.6 The Risk of Investment in New Drug Development
  7.3.7 Healthcare Budgetary Pressures and the Threat of Product Substitution
7.4 Social, Technological, Economic and Political (STEP) Analysis

8. RESEARCH INTERVIEWS

8.1 Interview with Dr Frank Peacock, Professor, Associate Chair and Research Director, Baylor College of Medicine, Houston, Texas
  8.1.1 Warfarin vs Novel Oral Anticoagulants
  8.1.2 The Unmet Needs of the Market
  8.1.3 The Antithrombotic R&D Pipeline
  8.1.4 Key Market Drivers and Restraints
8.2 Interview with Dr Walter Ageno, Associate Professor of Medicine, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
  8.2.1 Unmet Need
  8.2.2 Future Focus of Antithrombotic Therapy
  8.2.3 The Antithrombotic R&D Pipeline
  8.2.4 Key Market Drivers and Restraints
  8.2.5 Opportunities in the Market
8.3 Interview with Dr Maurice Petitou, Head of Preclinical Research and Development, Endotis Pharma
  8.3.1 EP217609: The First Neutralizable Anticoagulant
  8.3.2 Drug Targets Worth Exploring
  8.3.3 New Drug Potential
  8.3.4 Unmet Needs
8.4 Interview with Dr Jonathan L. Halperin, Professor of Medicine, Director of Clinical Cardiology Services, Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Medical Center, New York
  8.4.1 Unmet Needs
  8.4.2 New Findings
  8.4.3 Warfarin Replacement
  8.4.4 Areas Demanding Attention
  8.4.5 Key Market Restraints

9. CONCLUSIONS

9.1 World Market Overview to 2023
9.2 Leading Drug Classes
9.3 Leading Products
9.4 Leading National Markets
9.5 The Future of the Antithrombotic Drug Market
  9.5.1 Challenges
  9.5.2 Opportunities

List Of Tables

LIST OF TABLES

Table 3.1 Antithrombotic Drug Revenue by Therapeutic Class, 2011
Table 3.2 Antithrombotic Drugs: Revenues for World Market and Submarkets, 2011-2023
Table 3.3 Platelet Aggregation Inhibitors: Market Forecast, 2011-2023
Table 3.4 The Platelet Aggregation Inhibitors Market: Drivers and Restraints, 2013- 2023
Table 3.5 Anticoagulant Drug Market: Revenues by Class, 2011
Table 3.6 Anticoagulant Classes: Revenue Forecasts, 2011-2017
Table 3.7 Anticoagulant Classes: Revenue Forecasts, 2018-2023
Table 3.8 Heparins: Market Sector Forecast, 2011-2023
Table 3.9 The Heparins Market: Drivers and Restraints, 2013-2023
Table 3.10 Vitamin K Antagonists: Market Sector Forecast, 2011-2023
Table 3.11 The Vitamin K Antagonist Market: Drivers and Restraints, 2013-2023
Table 3.12 Direct Thrombin Inhibitors: Market Sector Forecast, 2011-2023
Table 3.13 Direct Thrombin Inhibitors Market: Drivers and Restraints, 2013-2023
Table 3.14 Direct Factor Xa Inhibitors: Market Sector Forecast, 2011-2023
Table 3.15 Direct Factor Xa Inhibitors Market: Drivers and Restraints, 2013-2023
Table 3.16 Fibrinolytics: Market Sector Forecast, 2011-2023
Table 3.17 The Fibrinolytics Market: Drivers and Restraints, 2013-2023
Table 4.1 Antithrombotic Drugs: Leading National Markets, 2011
Table 4.2 Antithrombotic Drugs: Market Shares by Country, 2011 and 2023
Table 4.3 Antithrombotic Drugs: Revenue Forecasts by Leading Country, 2011-2023
Table 4.4 US Antithrombotic Drug Market Forecast, 2011-2023
Table 4.5 The Japanese Antithrombotic Drug Market Forecast, 2011-2023
Table 4.6 The Leading European Antithrombotic Drug Markets (EU5), 2011-2023
Table 4.7 The Chinese Antithrombotic Drug Market Forecast, 2011-2023
Table 4.8 The Brazilian Antithrombotic Drug Market Forecast, 2011-2023
Table 4.9 The Indian Antithrombotic Drug Market Forecast, 2011-2023
Table 4.10 The Russian Antithrombotic Drug Market Forecast, 2011-2023
Table 5.1 Leading Antithrombotic Drugs: Revenues and Market Shares, 2011
Table 5.2 Top 10 Drugs: Revenue Forecasts, 2011-2023
Table 5.3 Plavix: Key Facts, 2012
Table 5.4 Plavix: Revenue Forecast, 2011-2023
Table 5.5 Lovenox: Key Facts, 2012
Table 5.6 Lovenox: Revenue Forecast, 2011-2023
Table 5.7 Enoxparin Sodium: Key Facts, 2012
Table 5.8 Enoxaparin Sodium: Revenue Forecast, 2011-2023
Table 5.9 Pradaxa: Key Facts, 2012
Table 5.10 Pradaxa: Revenue Forecast, 2011-2023
Table 5.11 Pletal: Key Facts, 2012
Table 5.12 Pletal: Revenue Forecast, 2011-2023
Table 5.13 Aspirin Cardio: Key Facts, 2012
Table 5.14 Aspirin Cardio: Revenue Forecast, 2011-2023
Table 5.15 Aggrenox: Key Facts, 2012
Table 5.16 Aggrenox: Revenue Forecast, 2011-2023
Table 5.17 Activase: Key Facts, 2012
Table 5.18 Activase: Revenue Forecast, 2011-2023
Table 5.19 Angiomax: Key Facts, 2012
Table 5.20 Angiomax: Revenue Forecast, 2011-2023
Table 5.21 Arixtra: Key Facts, 2012
Table 5.22 Arixtra: Revenue Forecast, 2011-2023
Table 5.23 Newly Launched Drugs, 2009-2012
Table 5.24 Effient: Key Facts, 2012
Table 5.25 Effient: Revenue Forecast, 2011-2023
Table 5.26 Brilinta: Key Facts, 2012
Table 5.27 Brilinta: Revenue Forecast, 2011-2023
Table 5.28 Xarelto: Key Facts, 2012
Table 5.29 Xarelto: Revenue Forecast, 2011-2023
Table 5.30 Eliquis: Key Facts, 2012
Table 5.31 Eliquis: Revenue Forecast, 2011-2023
Table 6.1 Platelet Aggregation Inhibitors: R&D Pipeline, 2012
Table 6.2 The Heparins R&D Pipeline, 2012
Table 6.3 The Vitamin K Antagonist Pipeline, 2012
Table 6.4 The Direct Thrombin Inhibitors Pipeline, 2012
Table 6.5 The Direct Factor Xa Inhibitors Pipeline, 2012
Table 6.6 The Fibrinolytics R&D Pipeline, 2012
Table 6.7 Other Antithrombotic Drugs: R&D Pipeline, 2012
Table 7.1 The Antithrombotic Drug Market: Main Drivers and Restraints, 2013
Table 7.2 The Antithrombotic Drug Market: Strengths and Weaknesses, 2013
Table 7.3 The Antithrombotic Drug Market: Opportunities and Threats, 2013
Table 7.4 STEP Analysis, 2013
Table 9.1 Antithrombotic Drugs: Overall World Revenue, 2011-2023

About

Plavix: The Leading Antithrombotic of 2011

In 2011, Plavix generated revenue of $9654m representing a market share of 42.57% (Table 5.1). Plavix has been a clinical and commercial success being the second highest revenue generating product in the global pharmaceutical market, falling just behind Lipitor. The success of Plavix was due to its broad label and strong data from major clinical trials. Also, it was recommended in guidelines for the treatment of ACS, peripheral arterial disease and stroke, and therefore hasgained doctors’ familiarity.However, when the US patent for Plavix expired in May 2012 the FDA approved several generic versions of the drug; Dr. Reddy's Laboratories, Gate Pharmaceuticals, Mylan and Teva Pharmaceuticals have gained approval for clopidogrel, as well as others. In Q2 2012, sales in the US fell by 59.9%. Revenue in Europe was also affected by generic competition which caused an 18.5% decline in revenue. However, patent protection in Europe still prevents the marketing of most generic versions of Plavix for ACS. In contrast, Plavix sales increased in both Japan and China, by 19% and 25% respectively. In Q3 2012, overall sales of Plavix had fallen by 96% to $64m, compared to Q3 2011.

Plavix Revenue Forecast, 2012-2023

Plavix sales dropped significantly in 2012 with annual growth of -73%. This was due to the loss of market exclusivity and subsequent introduction of generic competition in May of that year. This rate of revenue decline will decrease in subsequent years with a CAGR of -25% between 2011 and 2017. Revenue of Plavix will continue to tail off throughout the second half of the forecast period to $1600m in 2023 with a CAGR of -0.8% for that period.

Branded Competition

AstraZeneca’s Brilinta, approved by the FDA in July 2011 and in Europe in December 2010, offers certain advantages over Plavix. For example, it has been found to be slightly more effective in patients with acute coronary syndrome and can unlike Plavix, can be used with proton pump inhibitors. However, higher cost and twice-daily regime of Brilinta will likely make it less popular with patients. Plavix, on the other hand, is a well understood drug and will soon be less expensive once generics are available in the market. Therefore, we conclude that although Brilinta will pose competition to Plavix, it will not be an immediate threat. Eli Lilly’s Effient (Prasugrel) was approved by the FDA in 2009. Although Effient has shown promising results in the head-to-head trial, it is associated with more bleeding complications than Plavix. Overall, Effient has not performed as well in the market as expected and, thus, visiongain and other analysts conclude that Effient will not be a major threat to Plavix.